T he ductus arteriosus closes over the first few days of life in most newborns. In preterm infants, it may remain open even after 4-7 days of life leading to increased shunting of blood into the pulmonary circulation and potentially compromising circulation to systemic organs. This assumption is the keystone on which the decision to close the patent ductus arteriosus (PDA) in a preterm baby rests.
Though spontaneous closure of the ductus is the norm in term newborns, two-thirds of very low birth weight (VLBW) babies have spontaneous closure in the first seven days of life and only 30% of extremely low birth weight (ELBW) close their ductus during the neonatal period [1] . A PDA in a VLBW baby is associated (though not causal) with adverse outcomes like bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC) and death [2] . However, trials have not shown any definite change in these outcomes by treating a PDA. Treatment of PDA thus remains one of the most debated topics in neonatal medicine with no consensus on whether to treat, and when and how to treat! Nick Evans aptly calls it a "conundrum" [2] [3] [4] . Be that as it may, most neonatologists would prefer to attempt ductal closure in preterm neonates with symptoms or in those on respiratory support.
Hemodynamic significance of PDA in clinical practice is determined by echocardiographic assessment of size of PDA and its association with clinical signsmainly respiratory. Closure is attained either pharmacologically (with prostaglandin inhibitors) or surgically. In the year 1976, indomethacin was first used to treat PDA in a preterm neonate [5] . After that, ibuprofen came into use. A Cochrane meta-analysis comparing these two stated that ibuprofen was as effective as indomethacin in closing a PDA with lesser risk of NEC or transient renal insufficiency, thus being the drug of choice [6] . Hammerman, et al. [7] in 2009, first described the successful use of oral paracetamol for ductal closure in a case series of 5 preterm babies who either had contra-indications to or failed closure with indomethacin.
Paracetamol acts mainly by inhibiting peroxidase enzyme activity. It is a weak inhibitor of cyclo-oxygenase enzyme. Because of the ease of availability, lesser cost and wider margin of safety, paracetamol has generated interest among neonatologists as a potential first line drug for ductal closure. There have been two recent randomized controlled trails (RCTs) which have looked at efficacy of paracetamol as first line drug for closure of hemodynamically significant PDA in comparison to ibuprofen [8, 9] . A meta-analysis of these trials opined that paracetamol was as effective as oral ibuprofen. A cautionary note was introduced in view of animal studies suggesting adverse effects on developing brain after use of paracetamol. Thus the author advised that long-term neurological outcomes should be looked at regarding use of paracetamol in newborn [10] .
In this issue, Dash, et al. [11] have published a RCT comparing oral paracetamol with intravenous indomethacin with the primary outcome being closure of the PDA at 7 days. This is the first RCT that has compared oral paracetamol with indomethacin. The authors randomized 77 VLBW preterms having a PDA (diagnosis based on echocardiographic findings) within 48 hours of life to receive either paracetamol or indomethacin. PDA closure rates were 100% and 94.6% in the paracetamol and indomethacin groups, respectively. There were no differences in secondary outcomes such as need for surgical closure of PDA, gastrointestinal bleed, necrotizing enterocolitis, hepatotoxicity, hypothermia, renal dysfunction or mortality between the two groups. The authors have rightly pointed out that the study was underpowered to demonstrate the anticipated difference of efficacy between the two intervention drugs. As the study recruited neonates in the first 48 hours of life, some of these neonates might have had spontaneous closure of VOLUME 52 __ JULY 15, 2015 EDITORIALS PDA. Even with these limitations, this study will definitely add to the existing evidence on use of paracetamol in therapy for PDA.
Paracetamol can be used cautiously as the first line drug in the absence of indomethacin/ibuprofen or when these drugs are contraindicated. Larger studies comparing paracetamol versus indomethacin/ibuprofen in symptomatic PDA may be needed before paracetamol can be accepted as the first line drug in treatment of PDA. It would be worthwhile to also follow-up this cohort to see the neuro-developmental outcomes, and the same should be applicable to future RCTs using paracetamol for closure of PDA. sdkyurttutan@gmail.com W hether or not to treat all neonates with PDA remains controversial. Association of PDA with adverse outcomes suggests a need to intervene in neonates with PDA. However, pharmacological as well as surgical treatment strategies have failed to show promising long-term benefits. So, the dilemma remains! It is well known that the incidence of symptomatic and pathologic PDA is significantly higher in preterm infants with ≥28 weeks' gestation and/or ≥1000 g birth weight [1] . This suggests the need to select candidates for treatment of PDA judiciously. Treatment options for PDA include surgical and pharmacological modalities.
Conservative management includes fluid restriction, and high positive end-expiratory pressure (PEEP) and low inspiratory time (0.35s) during ventilation [2] . These approaches need more scientific evidence, including randomized controlled studies. Also, restricted fluid regimens and high PEEP are most difficult to follow in extremely low gestational ages (<28 weeks). Pharmacological therapy is thus the mainstay for treatment of PDA. Surgical therapy is often used as a last resort for treatment of PDA.
Indomethacin and ibuprofen act by blocking the conversion of arachidonic acid to prostaglandins, and have been adequately studied for ductal closure [3] . VOLUME 52 __ JULY 15, 2015 EDITORIALS However, due to their adverse effects, paracetamol came up into clinical practice as a new treatment option for PDA [1] . Paracetamol acts by directly inhibiting the activity of prostaglandin synthase. Unlike ibuprofen, it is thought to act on prostaglandin synthase at the peroxidase region of the enzyme. In 2011, Hammerman, et al. [4] first published used paracetamol in preterm infants with PDA. Thereafter, Oncel, et al. [5] [6] [7] published case series about enteral and/or intravenous paracetamol treatment in preterm infants with clinically significant PDA. These studies showed that paracetamol is effective for treatment of PDA in preterm infants.
In this issue of Indian Pediatrics, Dash, et al. [8] provide valuable new comparative data between enteral paracetamol and intravenous indomethacin for closure of PDA in preterm neonates. The investigators prospectively enrolled 171 preterm infants with birthweight ≥1500 g, within 48 hours of birth, and with one of the following echocardiographic criteria: duct size >1.5 mm, a left atrium-to-aorta ratio >1.5. Finally, 38 preterm neonates were randomized to receive enteral paracetamol and 39 were randomized to receive intravenous indomethacin. PDA closure rates with oral paracetamol and indomethacin were 100% and 95%, respectively. There were no significant differences between two groups for side effects or other comorbidities. The PDA closure rates were quite high in both study groups (>95%) which may be related to the high mean gestational age (31.6 weeks). In contrast, PDA closure rate with paracetamol therapy in an earlier study [1] was 72.5%. The other striking result of this study is high intestinal bleeding rate in paracetamol group (26.3%). In a study [7] from our group, we did not see any intestinal side effects of paracetamol groups. Most of the paracetamol solutions have osmolalities about 4000 (±1000) mOsmol/L which need to be diluted to reduce it tenfold to 400 mOsmol/L. The excessive intestinal problems in this study may have been related to the high osmolality of paracetamol solutions used for treatment. The results of present study are similar to those of two randomized controlled studies in the past [1, 9] . All these studies showed that paracetamol is a safe and successful alternative agent for pharmacological treatment of PDA. However, there is a need for further studies evaluating the effects, especially the long-term neurodevelopmental outcome in infants treated with paracetamol.
Funding: None; Competing interest: None stated. VOLUME 52 __ JULY 15, 2015 EDITORIALS S nakebite is one of the most neglected public health issues in rural areas causing significant death and disability. Actual burden of snakebite remains elusive due to serious under-reporting. Majority of victims die even before reaching hospital [1, 2] . South Asia is the most heavily affected region of the globe. The highest figures reported from Asia, so far, come from a community-based survey conducted in South-East Nepal in 2002 [1] . In India alone, about 45,900 people are estimated to die from snake bites according to Million Death Study [2] .
The Indian subcontinent is well known for its snake biodiversity. However, species of the family of Elapidae and Viperidae are responsible for most deaths and disabilities related to snakebite. Among the true vipers, Russell's viper (Daboiarusselii) is associated with the highest morbidity and mortality. In Anuradhapura District, Sri Lanka, up to 73% of all admitted snakebites were attributed to this species [3] , whose distribution extends from the Indus valley of Pakistan in West and Kashmir, India in the North to the foothills of the Himalayas in Nepal and Bhutan, and to Bangladesh in the East.
Snake inflicted morbidity and death occurs through cytotoxic, hematotoxic, or neurotoxic mechanisms. Apart from local swelling and tissue damage, viperidae venom can also induce coagulopathy and platelet dysfunction leading to systemic bleeding and hemorrhage from the local site. Intracranial hemorrhage, including pituitary hemorrhage, and multiorgan dysfunction may occur. In addition, envenoming by Russell's viper can cause generalized rhabdomyolysis induced by PhospholipaseA2, which may cause myoglobinemia, hyperkalemia, and acute kidney injury (AKI) [4] . AKI may also result from the direct action of some venoms and associated hypotension due to bleeding. Venomous snakebite accounts for a notable proportion of victims with AKI in regions with viper envenoming including in India, as was also witnessed in the study by Krishnamurthy, et al. [5] in this issue of Indian Pediatrics.
Factors that determine the outcome of snakebite management are multifactorial [6] . Delay in seeking health care due to misbelief, difficult terrain, inadequate knowledge and skill of medical fraternity, and lack of [7] . Similarly, most of the time snakebite victims do not receive appropriate dose of antivenom and/or assisted ventilation when needed [8] .
Since AKI is seen to occur in a majority of snakebite victims, lack of renal replacement therapy in rural/remote areas where most snakebites occur, and late referral to the center with facilities for dialysis and mechanical ventilation are some of the major determinants of fatalities, which need to be addressed. This preventable and reversible cause of AKI is more relevant in the context of The International Society of Nephrology initiative, called "0 by 25" program, which aims to eliminate preventable death from AKI in the poorest parts of Africa, Asia and Latin America by 2025 [9] .
Education of the communities as well as caregivers on how to avoid and protect from snakebites by wearing protective boots in paddy fields or while performing outdoor activities, not sleeping on ground, using mosquito nets, seeking early medical help, and avoiding arterial tourniquet can help reduce consequences of snakebite and envenoming [10] . This is especially relevant in pediatric snakebites as the venom can affect children more quickly due to their low body mass. This may help mitigate the death and disabilities related to snakebite envenoming. S ince reporting is not mandatory in many regions of the world, snakebites often go unreported [1] . Consequently, no large-scale study has ever been conducted to determine the incidence of snakebites. However, some estimates put the number at 5.4 million snakebites, 2.5 million envenomings, resulting in perhaps 125,000 deaths [1] . According to the most conservative estimates, at least 81,000 snake envenomings and 11,000 fatalities occur in India each year, making it the most heavily affected country in the world [1] . It is most unfortunate that despite a large population getting bitten by snakes every year and a large number succumbing to its complications, not much has been done to handle this preventable envenomation. Ignorance about the problem and the prevalent cultural practices delay arrival of patients to equipped health centers. Moreover, the anti-snake venoms (ASV) available in market are not effective against venoms of all snakes responsible for envenomation, adding to the mortality. More research in this area is needed to make suitable and safe ASVs to take care of regional variations in distribution of snakes. Community education to population at-risk regarding the behavior of snakes inhabiting their region, features of snake envenomation, do's and don'ts after a snake bite, and more specifically the transportation of a victim to a health centre will change the scenario favorably.
Of the roughly 3,000 known species of snake found worldwide, only 15% are considered dangerous to humans [1, 2] . There are two major families of venomous snakes, Elapidae and Viperidae. Three hundred and twenty five species in 61 genera are recognized in the family Elapidae [3] , and 224 species in 32 genera are recognized in the family Viperidae [4] . In addition, the most diverse and widely distributed snake family, the Colubridae, has approximately 700 venomous species [5] but only five genera -boomslangs, twig snakes, keelback snakes, green snakes, and slender snakes -have caused human fatalities [5] . In the Indian subcontinent, almost all snakebite deaths have traditionally been attributed to the big four -Russell's viper, Indian cobra, saw-scaled viper and the common krait [6] . However, studies have shown that the hump-nosed viper, previously considered essentially harmless and misidentified as the saw-scaled viper, is capable of delivering a fatal bite [7] . In regions of Kerala, India, it may be responsible for nearly 10% of venomous bites [7] . Commonly used antivenoms in India do not appear to be effective against hump-nosed viper bites [7] . The Malayan pit viper and banded krait are two other species involved in a significant number of venomous bites.
The Madras Crocodile Bank Trust and Centre for Herpetology (MCBT), in collaboration with scientists at the Indian Institute of Science (IIS) and National Center for Biological Sciences (NCBS) and the Global Snakebite Initiative have begun a project that will initially concentrate on Russell's viper which is responsible for many serious and fatal bites. Venom will be collected from ten different geographic areas around India, quickly frozen using a new Geological Survey of VOLUME 52 __ JULY 15, 2015 EDITORIALS India (GSI)-developed protocol and then transferred to toxicologists at the IIS for studies of how effectively it is neutralized by Indian antivenoms. Detailed proteomic studies will follow. Results of these studies should improve the quality and potency of Indian anti-venoms.
Definitive data which can accurately determine the level of envenomation, e.g ELISA testing, needs to be employed as symptomatology is not a useful guide to the level of envenomation. It is important that a single ASV regimen be adhered to for treating envenomation. The usual recommended initial dosage of ASV is 100 mL of polyvalent ASV for adults and children, based on published research that Russell's Viper injects on an average about 63 mg of venom. The total venom injected can range from 5 mg to 147 mg; therefore, the total requirement of ASV is between 100 mL and 250 mL. The initial drip rate of ASV should be very slow and patients should be watched carefully for any adverse reaction. Children must receive the same dose of ASV as adults as the dose of venom injected is same. The correction of coagulopathy is the most important criteria to discontinue ASV treatment which sometimes takes several days and may even require blood and blood products. Adverse reactions to ASV include anaphylaxis which may require administration of adrenaline intramuscularly. In old patients, administration of intravenous hydrocortisone and H-1 and H-2 blockers may be particularly useful as intramuscular adrenaline can lead to a fatal outcome. In neurotoxic poisoning after the first dose has been given (100 mL of ASV) which neutralizes 120 mg of poison, another dose may be repeated after one hour in case the patient worsens or shows no improvement. No further ASV is required usually, but neostigmine and mechanical ventilation should be continued, if needed. In case of evidence of acute kidney injury (AKI) as seen commonly in viper bites, and if there is passage of dark brown urine suggesting myoglobinuria or hemoglobinuria, adequate hydration, correction of hydration and even dialysis may be needed. To reduce mortality due to snake envenomation, it is important to identify and predict which patients are likely to suffer from serious manifestations. In the study by Krishnamurthy, et al. [9] published in this issue of Indian Pediatrics, AKI was found to be associated with viper envenomation in patients with shock, bleeding manifestations and those receiving native treatment. Other studies have reported a high association of snake envenomation-related AKI in patients with albuminuria, raised bilirubin levels, and younger age [10, 11] . Identification of high risk factors and early administration of ASV will certainly aid to curb mortality in snake envenomation.
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